Factors determining visual outcome in endogenous Candida endophthalmitis

Retina

Volumn 32, Issue 6, 2012, Pages 1129-1134

  Sallam, Ahmed ^a   Taylor, Simon R J ^a,b   Khan, Aldrin ^a   McCluskey, Peter ^c,e   Lynn, William A ^d   Manku, Kiran ^c   Pacheco, Patricio A ^a   Lightman, Sue ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d EALING HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Candida; candida endophthalmitis; corticosteroids; endogenous fungal endophthalmitis; fluconazole; vitrectomy

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; FLUCONAZOLE; ITRACONAZOLE; MICONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA ENDOPHTHALMITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; RETINA DETACHMENT; RETROSPECTIVE STUDY; VISUAL IMPAIRMENT; VITRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CANDIDA; ENDOPHTHALMITIS; EYE INFECTIONS, FUNGAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; RISK FACTORS; VISUAL ACUITY; VITRECTOMY;

EID: 84861816708     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822d3a34     Document Type: Article

References (30)

1. Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmi-tis. Ophthalmic Surg Lasers 1997;28:185-194.
2. Feman SS, Nichols JC, Chung SM, Theobald TA. Endophthal-mitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc 2002;100:67-70; discussion 70-61.
3. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137:820-825.
4. Takebayashi H, Mizota A, Tanaka M. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefes Arch Clin Exp Ophthalmol 2006;244:816-820.
5. Sarria JC, Bradley JC, Habash R, et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005;40:e46-e48.
6. O'Day DM, Head WS, Robinson RD, et al. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res 1985;4:131-134.
7. Louie A, Liu W, Miller DA, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 1999;43: 2831-2840.
8. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001;44:125-135.
9. Coats ML, Peyman GA. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992;12:46-51.
10. Majji AB, Jalali S, Das T, Gopinathan U. Role of intravitreal dexamethasone in exogenous fungal endophthalmitis. Eye (Lond) 1999;13:660-665.
11. Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and cas-pofungin. Am J Ophthalmol 2005;139:135-140.
12. Chakrabarti A, Shivaprakash MR, Singh R, et al. Fungal en-dophthalmitis: fourteen years' experience from a centre in India. Retina 2008;28:1400-1407.
13. Smiddy WE. Treatment outcomes of endogenous fungal en-dophthalmitis. Curr Opin Ophthalmol 1998;9:66-70.
14. Holland GN. Endogenous fungal infections of the retina and choroid. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP, eds. Retina. Philadelphia, PA: Elsevier; 2006:1695-1696.
15. Tanaka M, Kobayashi Y, Takebayashi H, et al. Analysis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis. A retrospective 12-year study of 79 eyes of 46 patients. Retina 2001;21:203-209.
16. Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular can-didiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994;101:1302-1309.
17. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467-471.
18. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140: 509-516.
19. Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthal-mitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 2003;82:97-105.
20. Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina 2005;25: 746-750.
21. Okhravi N, Adamson P, Mant R, et al. Polymerase chain reaction and restriction fragment length polymorphism mediated detection and speciation of Candida spp causing intraocular infection. Invest Ophthalmol Vis Sci 1998;39:859-866.
22. Laatikainen L, Tuominen M, von Dickhoff K. Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol 1992;113:205-207.
23. Christmas NJ, Smiddy WE. Vitrectomy and systemic flucona-zole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1996;27:1012-1018.
24. Luttrull JK, Wan WL, Kubak BM, et al. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995;119:477-481.
25. Goa KL, Barradell LB. Fluconazole. An update of its pharma-codynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompro-mised patients. Drugs 1995;50:658-690.
26. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410.
27. Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003;52: 71-77.
28. Riddell J, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011;52:648-653.
29. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by anti-fungal therapy. Clin Infect Dis 1998;27:1130-1133.
30. Narendran N, Balasubramaniam B, Johnson E, et al. Five-year retrospective review of guideline-based management of fungal endophthalmitis. Acta Ophthalmol 2008;86:525-532.